Newsletters and Deep Dive digital magazine
The FDA has given a green light to two formulations of Pfizer’s tafamidis that have become the first drugs to be approved in the US for cardiomyopathy associated with rare disease transthyr
Pfizer is finally closing on approval of its rare disease therapy tafamidis in the US, several years after it first reached the market in Europe.
Pfizer’s heart disease drug, tafamidis, reduces mortality rates in patients, according to the top-line results of a phase 3 trial.
Company will cut its headcount by 35%, as it waits for an FDA decision on its diabetes DTx.
An inside guide to unlocking clinical research in the UK